Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study

Visseren, 2021, ESC Scientific Document Group: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J, 42, 3227, 10.1093/eurheartj/ehab484 Matsuura, 2019, Highlighting residual atherosclerotic cardiovascular disease risk, Arterioscler Thromb Vasc Biol, 39, e1, 10.1161/ATVBAHA.118.311999 Mach, 2020, ESC Scientific Document Group: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J, 41, 111, 10.1093/eurheartj/ehz455 Kronenberg, 2022, Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement, Eur Heart J, 43, 3925, 10.1093/eurheartj/ehac361 Ward, 2021, Lipoprotein (a) and diabetes mellitus: causes and consequences, Curr Opin Endocrinol Diabetes Obes, 28, 181, 10.1097/MED.0000000000000597 Tsimikas, 2018, In search of a physiological function of lipoprotein (a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes, J Lipid Res, 59, 741, 10.1194/jlr.C085639 Skoumas, 2007, Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia, Metabolism, 56, 135, 10.1016/j.metabol.2006.09.007 Skoumas, 2014, Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia, Atherosclerosis, 237, 140, 10.1016/j.atherosclerosis.2014.08.047 2002, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Utermann, 2001, Lipoprotein(a), 2753 Mora, 2010, Lipoprotein(a) and risk of type 2 diabetes, Clin Chem, 56, 1252, 10.1373/clinchem.2010.146779 Tolbus, 2017, Kringle IV Type 2, not low Lipoprotein (a), as a cause of diabetes: a novel genetic approach using snps associated selectively with Lipoprotein(a) concentrations or with Kringle IV type 2 repeats, Clin Chem, 63, 1866, 10.1373/clinchem.2017.277103 Kamstrup, 2013, Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study, Lancet Diabetes Endocrinol, 1, 220, 10.1016/S2213-8587(13)70064-0 Langsted, 2021, Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study, Eur Heart J, 42, 1147, 10.1093/eurheartj/ehaa1085 Ye, 2014, The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?, Diabetes, 63, 332, 10.2337/db13-1144 Kaya, 2017, Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes, Postgrad Med, 129, 611, 10.1080/00325481.2017.1342508 Paige, 2017, Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature, Cardiovasc Diabetol, 16, 38, 10.1186/s12933-017-0520-z Veerkamp, 2005, Role of insulin resistance in familial combined hyperlipidemia, Arterioscler Thromb Vasc Biol, 25, 1026, 10.1161/01.ATV.0000160612.18065.29 Vaverková, 2017, Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects, Physiol Res, 66, S113, 10.33549/physiolres.933583 Zhang, 2018, Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus, Nutr Metab Cardiovasc Dis, 28, 980, 10.1016/j.numecd.2018.05.010 Saeed, 2019, Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the Atherosclerosis Risk in Communities study, Atherosclerosis., 282, 52, 10.1016/j.atherosclerosis.2018.12.022 Boronat, 2012, High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc Diabetol., 11, 81, 10.1186/1475-2840-11-81 Mu-Han-Ha-Li, 2018, LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk, J Lipid Res, 59, 884, 10.1194/jlr.P082792 Gudbjartsson, 2019, Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes, J Am Coll Cardiol, 74, 2982, 10.1016/j.jacc.2019.10.019 Buchmann, 2017, Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin, Acta Diabetol, 54, 1031, 10.1007/s00592-017-1036-4 Kane, 2021, Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus, Curr Opin Pharmacol, 61, 21, 10.1016/j.coph.2021.08.013 Wilson, 2022, Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. a scientific statement from the National Lipid Association, J Clin Lipidol, 16, e77, 10.1016/j.jacl.2022.08.007 Schwartz, 2021, ODYSSEY OUTCOMES committees and investigators: relation of Lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment, Diabetes Care, 44, 1219, 10.2337/dc20-2842 Schwartz, 2021, Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol, J Am Coll Cardiol, 78, 421, 10.1016/j.jacc.2021.04.102